Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which cardiac muscle performance is compromised.
This week, we have a conversation with the CEO of Cytokinetics, Robert Blum, about the company’s aficamten, its next-in-class cardiac myosin inhibitor, prior to results from a phase 3 clinical trial in obstructive hypertrophic cardiomyopathy.
00:54-02:32: About Cytokinetics
02:32-04:11: What are the current treatments for cardiovascular conditions?
04:11-05:44: About cardiovascular disease
05:44-08:59: What is aficamten?
08:59-09:12: How is it administered?
09:12-10:04: Where is aficamten on the path to commercialization?
10:04-12:06: What does this mean for patients?
12:06-12:42: What will you be presenting in Portugal?
12:42-16:06: Could aficamten have other applications?
16:06-16:50: What is CK-136?
16:50-18:02: What is omecamtiv mecarbil?
18:02-20:26: Cytokinetics’ business model
Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!
Stay updated by subscribing to our newsletter
